Breaking World Pharma News

Fifth Lilly Oncology on Canvas Art Competition invites all touched by cancer

Thu, 09 Feb 2012 22:00:00 +0000

Get your canvases, paintbrushes and cameras ready - the subject is cancer and you are the storyteller. Lilly Oncology and the National Coalition for Cancer Survivorship (NCCS) announced the launch of the 2012 Lilly Oncology On Canvas: Expressions of a Cancer Journey Art Competition and Exhibition.

Sanofi fourth-quarter and full-year net sales

Wed, 08 Feb 2012 22:00:01 +0000

In the fourth quarter of 2011, Sanofi generated sales of €8,508 million, up 8.8% on a reported basis. Exchange rate movements had a negative effect of 0.4 percentage points.

Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex

Wed, 08 Feb 2012 22:00:00 +0000

Sanofi (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced that Apotex has made payment in the amount of $442,209,362 to Sanofi and Bristol-Myers Squibb to satisfy the damages ruling of the Plavix® (clopidogrel bisulfate) patent infringement case against Apotex.

Roche in 2011: Strong results and positive outlook

Tue, 07 Feb 2012 22:00:00 +0000

The Roche Group posted strong operating results in a challenging market in 2011. Core operating profit grew faster than sales, and Core Earnings per Share increased by 11% at constant exchange rates (-4% in Swiss francs).

New technology to tackle treatment-resistant cancers

Mon, 06 Feb 2012 22:00:00 +0000

Free-flowing cancer cells have been mapped with unprecedented accuracy in the bloodstream of patients with prostate, breast and pancreatic cancer, using a brand new approach, in an attempt to assess and control the disease as it spreads in real time through the body, and solve the problem of predicting response and resistance to therapies.

Warfarin and aspirin are similar in heart failure treatment

Sun, 05 Feb 2012 22:00:00 +0000

In the largest and longest head-to-head comparison of two anti-clotting medications, warfarin and aspirin were similar in preventing deaths and strokes in heart failure patients with normal heart rhythm, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

Websites advertising cholesterol-lowering drugs of poor quality

Thu, 02 Feb 2012 22:00:00 +0000

A new study published in the journal Pharmacoepidemiology & Drug Safety reveals that internet sites selling prescription statins directly to consumers are widespread, and that most websites advertising statins for sale to the general public contain very poor levels of information relevant to safe use of the medicine and side effects.

AstraZeneca fourth quarter and full year results 2011

Thu, 02 Feb 2012 08:00:00 +0000

AstraZeneca's revenue in the fourth quarter was unchanged at CER and on an actual basis as exchange rate movements were neutral to reported revenue. Adjusted for the disposal of Astra Tech, revenue growth was 2 percent.

Protein structures give disease clues

Wed, 01 Feb 2012 22:00:00 +0000

Using some of the most powerful nuclear magnetic resonance equipment available, researchers at the University of California, Davis, are making discoveries about the shape and structure of biological molecules - potentially leading to new ways to treat or prevent diseases such as breast cancer and Alzheimer's disease.

Pfizer reports fourth-quarter and full-year 2011 results

Tue, 31 Jan 2012 22:00:00 +0000

Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2011. Fourth-quarter 2011 revenues were $16.7 billion, a decrease of 4% compared with $17.4 billion in the year-ago quarter, which reflects an operational decline of $765 million, or 5%, and the favorable impact of foreign exchange of $157 million, or 1%.

Novartis extends commitment to help achieve final elimination of leprosy

Mon, 30 Jan 2012 22:00:00 +0000

Novartis will continue its work with the World Health Organization (WHO) toward a world free of leprosy by extending its drug donation of multidrug therapy (MDT) medicines to treat leprosy through the year 2020.

Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion

Sun, 29 Jan 2012 22:00:01 +0000

Amgen (NASDAQ: AMGN) reported total revenue increased 3 percent during the fourth quarter of 2011 to $3,973 million versus $3,841 million in the fourth quarter of 2010. For the full year 2011, total revenue increased 4 percent to $15,582 million from $15,053 million in 2010.

Alzheimer's Challenge 2012: seeking new tools to help improve Alzheimer's care

Sun, 29 Jan 2012 22:00:00 +0000

Pfizer Inc. (NYSE: PFE), together with its collaborator on the Alzheimer's Immunotherapy Program (AIP), Janssen Alzheimer Immunotherapy, and the Geoffrey Beene Gives Back® Alzheimer's Initiative introduced the Alzheimer's Challenge 2012 at the Care Innovations Summit in Washington, D.C.

Bristol-Myers Squibb delivers solid fourth quarter capping a year highlighted by new product approvals

Thu, 26 Jan 2012 22:00:00 +0000

Bristol-Myers Squibb Company (NYSE: BMY) announced solid financial results for the fourth quarter of 2011. This concludes a year in which the Company received important new product approvals for YERVOY® and NULOJIX® in both the U.S. and Europe, and ELIQUIS® in Europe for the prevention of venous thromboembolic events.

Amgen to Acquire Micromet

Wed, 25 Jan 2012 22:00:01 +0000

Amgen (NASDAQ:AMGN) and Micromet, Inc. (NASDAQ:MITI) today announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany with its research and development (R&D) center in Munich and headquarters in Rockville, Md., for $11 per share in cash.

Novartis delivers strong underlying financial performance in 2011

Wed, 25 Jan 2012 22:00:00 +0000

Novartis' net sales rose 4% (+5% cc) to USD 14.8 billion in the fourth quarter. The strengthening of the US dollar against most major currencies negatively impacted sales by 1 percentage point.

Abbott reports double-digit ongoing earnings-per-share growth in fourth quarter and full-year 2011

Wed, 25 Jan 2012 12:00:00 +0000

Abbott's worldwide sales increased 4.1 percent to $10.4 billion, including a favorable 0.2 percent effect of foreign exchange. Emerging markets sales were $2.5 billion, representing nearly 25 percent of total sales, with particularly strong growth in Nutritionals, Vascular and Diagnostics.

Novo Nordisk establishes type 1 diabetes R&D center in Seattle

Tue, 24 Jan 2012 22:00:00 +0000

Novo Nordisk will establish a type 1 diabetes R&D center in Seattle, US. The new center will combine Novo Nordisk's history of innovation and leadership in diabetes treatment with the company's growing expertise in immunotherapy.

Roche supports cancer care development program in Ethiopia

Mon, 23 Jan 2012 22:00:01 +0000

Roche announced a grant to the Albert Einstein College of Medicine of Yeshiva University in New York City, which will be used for the establishment of a program to improve basic cancer care in Ethiopia. The grant funding comes from the Roche African Research Foundation.

Rising Interest of Big Pharma Creates Immense Growth Potential for Contract Manufacturing Organisations

Mon, 23 Jan 2012 22:00:00 +0000

Increasingly, big pharma is viewing the outsourcing of pharmaceutical manufacturing as a strategic move that would enable them to focus on their core competencies such as R&D. At the same time, the patent expiry of key blockbuster drugs worth $45 billion and biologics worth $30 billion is expected to reduce the capacity utilisation rates of their manufacturing facilities,